GALECTIN THERAPEUTICS INC - 8-K Filing

Galectin Therapeutics reports Q3 2026 net loss of $3.6 million and announces debt-to-equity conversion of $105.8 million. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $GALT

Read the full article at SEC EDGAR

More Regulatory news